date:Nov 23, 2012
The Australian Competition and Consumer Commission (ACCC) has announced that it would not oppose Nestl's $11.85bn deal to acquire Pfizer's infant nutrition business. However, the commission asked Nestl to license its brand portfolio in the country to an independent purchaser.
This court enforceable undertaking requires Nestl to sell an exclusive ten year licence for Pfizer Nutrition's infant nutrition S-26/SMA brand portfolio in Australia to an independent purchaser to be approved by the ACCC.